Compare ONFO & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONFO | ENVB |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.0M |
| IPO Year | 2022 | N/A |
| Metric | ONFO | ENVB |
|---|---|---|
| Price | $0.73 | $4.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | ★ 67.3K | 61.8K |
| Earning Date | 11-17-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,238,989.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 70.54 | N/A |
| 52 Week Low | $0.59 | $3.50 |
| 52 Week High | $1.95 | $66.78 |
| Indicator | ONFO | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 44.37 |
| Support Level | $0.70 | $3.67 |
| Resistance Level | $0.85 | $4.24 |
| Average True Range (ATR) | 0.07 | 0.30 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 52.31 | 61.64 |
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place. The company operates in two business segments: Business to Business (B2B) and Business to Consumers (B2C). The majority of its revenue is generated from the Business-to-Business (B2B) segment, which includes the results of operations of Eastern Standard, RevenueZen, DDS Rank, SEO Butler, Contentellect, DealPipe, and Onfolio LLC.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.